{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-086454","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.574673+00:00","generated_at":"2026-06-24T03:28:57.719516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances","bullets":["Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.","Net loss of $3.6M for Q2 2022, narrowed from $5.9M in Q2 2021 due to lower R&D and G&A.","NXP800 Phase 1a dose-escalation ongoing; Phase 1b expansion expected Q1 2023; FDA cleared IND, U.S. and U.K. enrolling.","NXP900 IND-enabling studies on track for 2022 completion; preclinical data in medulloblastoma presented.","Completed $15.9M private placement in August 2022, extending cash runway into H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-086454","json":"https://secwatch.observer/filing/0001104659-22-086454.json","markdown":"https://secwatch.observer/filing/0001104659-22-086454.md","text":"https://secwatch.observer/filing/0001104659-22-086454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/0001104659-22-086454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/tm2222617d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:28:57.719516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}